Zacks
How Much Upside is Left in Corbus Pharmaceuticals (CRBP)? Wall Street Analysts Think 318.33%
📈
AI Sentiment
Highly Positive
9/10
- Home
- CRBP
as of 03-13-2026 4:00pm EST
$9.41
$0.18
-1.88%
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | NORWOOD |
| Market Cap: | 134.8M | IPO Year: | 2014 |
| Target Price: | $45.60 | AVG Volume (30 days): | 182.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.90 | EPS Growth: | -60.33 |
| 52 Week Low/High: | $4.64 - $20.56 | Next Earning Date: | 06-15-2026 |
| Revenue: | $4,822,272 | Revenue Growth: | 97.62% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 99.00% |
| P/E Ratio: | -1.63 | Index: | N/A |
| Free Cash Flow: | -64498000.0 | FCF Growth: | N/A |
AI-Powered CRBP Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 78.66%
78.66%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Corbus Pharmaceuticals Holdings Inc. (CRBP)
Smethurst Dominic
Sell
Chief Medical Officer
CRBP Mar 2, 2026
Avg Cost/Share
$8.30
Shares
6,097
Total Value
$50,601.44
Owned After
89,790
SEC Form 4
Hodgson Ian
Sell
Chief Operating Officer
CRBP Feb 17, 2026
Avg Cost/Share
$7.38
Shares
847
Total Value
$6,253.40
Owned After
51,080
SEC Form 4
Moran Sean F.
Sell
Chief Financial Officer
CRBP Feb 13, 2026
Avg Cost/Share
$7.78
Shares
4,701
Total Value
$36,587.88
Owned After
96,694
SEC Form 4
Cohen Yuval
Sell
Chief Executive Officer
CRBP Feb 13, 2026
Avg Cost/Share
$7.78
Shares
13,871
Total Value
$107,952.44
Owned After
174,316
SEC Form 4
Smethurst Dominic
Sell
Chief Medical Officer
CRBP Feb 3, 2026
Avg Cost/Share
$8.09
Shares
3,285
Total Value
$26,574.99
Owned After
89,790
SEC Form 4
Hodgson Ian
Sell
Chief Operating Officer
CRBP Feb 3, 2026
Avg Cost/Share
$8.09
Shares
2,415
Total Value
$19,537.11
Owned After
51,080
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Smethurst Dominic | CRBP | Chief Medical Officer | Mar 2, 2026 | Sell | $8.30 | 6,097 | $50,601.44 | 89,790 | |
| Hodgson Ian | CRBP | Chief Operating Officer | Feb 17, 2026 | Sell | $7.38 | 847 | $6,253.40 | 51,080 | |
| Moran Sean F. | CRBP | Chief Financial Officer | Feb 13, 2026 | Sell | $7.78 | 4,701 | $36,587.88 | 96,694 | |
| Cohen Yuval | CRBP | Chief Executive Officer | Feb 13, 2026 | Sell | $7.78 | 13,871 | $107,952.44 | 174,316 | |
| Smethurst Dominic | CRBP | Chief Medical Officer | Feb 3, 2026 | Sell | $8.09 | 3,285 | $26,574.99 | 89,790 | |
| Hodgson Ian | CRBP | Chief Operating Officer | Feb 3, 2026 | Sell | $8.09 | 2,415 | $19,537.11 | 51,080 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Mar 9, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLMar 9, 2026 · 100% conf.
AI Prediction SELL
1D
-1.87%
$7.99
Act: +1.85%
5D
-3.66%
$7.84
20D
+1.02%
$8.22
Price: $8.14 Prob +5D: 0% AUC: 1.000
0001193125-26-097582
8-K
false000159509700015950972026-03-092026-03-09
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 9, 2026
CORBUS PHARMACEUTICALS HOLDINGS, INC.
(Exact name of Registrant as Specified in Its Charter)
Delaware
001-37348
46-4348039
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
500 River Ridge Drive
Norwood, Massachusetts
02062
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (617) 963-0100
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
CRBP
The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. Corbus Pharmaceuticals Holdings, Inc. (the “Company”) issued a press release on March 9, 2026, disclosing financial information and operating metrics for its fiscal year ended December 31, 2025 and discussing its business outlook. A copy of the Company’s press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Item 7.01 Regulation FD Disclosure. See “Item 2.02 Results of Operations and Financial Condition” above.
The Company also updated its presentation used by management to describe its business. A copy of the presentation is furnished as Exhibit 99.2 and is incorporated herein by reference.
The information in this Current Report on Form 8-K under Items 2.02 and 7.01, including the information contained in Exhibit 99.1 and 99.2, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by a specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) The following exhibit is furnished with this report:
Exhibit No.
Description
99.1
Press Release issued by Corbus Pharmaceuticals Holdings, Inc. dated March 9, 2026.
99.2
Investor Presentation
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Corbus Pharmaceuticals Holdings, Inc.
Date:
March 9, 2026
By:
/s/ Yuval Cohen
Name: Yuval Cohen Title: Chief Executive Officer
2025 Q3 Q3 2025 Earnings
8-K BUY Nov 12, 2025 · 100% conf.
2025
Q3
Q3 2025 Earnings
8-K BUYNov 12, 2025 · 100% conf.
AI Prediction BUY
1D
+0.88%
$11.29
Act: -1.07%
5D
+12.33%
$12.57
Act: +5.63%
20D
+49.77%
$16.76
Act: -13.85%
Price: $11.19 Prob +5D: 100% AUC: 1.000
0001193125-25-276062
8-K
0001595097false00015950972025-11-122025-11-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 12, 2025
CORBUS PHARMACEUTICALS HOLDINGS, INC.
(Exact name of Registrant as Specified in Its Charter)
Delaware
001-37348
46-4348039
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
500 River Ridge Drive
Norwood, Massachusetts
02062
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (617) 963-0100
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
CRBP
The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. Corbus Pharmaceuticals Holdings, Inc. (the “Company”) issued a press release on November 12, 2025, disclosing financial information and operating metrics for its fiscal quarter ended September 30, 2025 and discussing its business outlook. A copy of the Company’s press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Item 7.01 Regulation FD Disclosure. See “Item 2.02 Results of Operations and Financial Condition” above.
The information in this Current Report on Form 8-K under Items 2.02 and 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by a specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) The following exhibit is furnished with this report:
Exhibit No.
Description
99.1
Press Release issued by Corbus Pharmaceuticals Holdings, Inc. dated November 12, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Corbus Pharmaceuticals Holdings, Inc.
Date:
November 12, 2025
By:
/s/ Yuval Cohen
Name: Yuval Cohen Title: Chief Executive Officer
2025 Q2 Q2 2025 Earnings
8-K Aug 5, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 5, 2025
0000950170-25-102447
8-K
false000159509700015950972025-08-052025-08-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 5, 2025
CORBUS PHARMACEUTICALS HOLDINGS, INC.
(Exact name of Registrant as Specified in Its Charter)
Delaware
001-37348
46-4348039
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
500 River Ridge Drive
Norwood, Massachusetts
02062
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (617) 963-0100
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
CRBP
The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. Corbus Pharmaceuticals Holdings, Inc. (the “Company”) issued a press release on August 5, 2025, disclosing financial information and operating metrics for its fiscal quarter ended June 30, 2025 and discussing its business outlook. A copy of the Company’s press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Item 7.01 Regulation FD Disclosure. See “Item 2.02 Results of Operations and Financial Condition” above.
The information in this Current Report on Form 8-K under Items 2.02 and 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by a specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) The following exhibit is furnished with this report:
Exhibit No.
Description
99.1
Press Release issued by Corbus Pharmaceuticals Holdings, Inc. dated August 5, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Corbus Pharmaceuticals Holdings, Inc.
Date:
August 5, 2025
By:
/s/ Yuval Cohen
Name: Yuval Cohen Title: Chief Executive Officer
Latest Corbus Pharmaceuticals Holdings Inc. News
CRBP Breaking Stock News: Dive into CRBP Ticker-Specific Updates for Smart Investing
Compare CRBP vs Leading Stocks
See how CRBP stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CRBP Corbus Pharmaceuticals Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.